Dergiler / Haydarpaşa Numune Medical Journal / 2020 / Cilt: 60 - Sayı: 4

A Case of Increased Creatin Kinase Level Caused by Daptomycin

Sayfa
445–447
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Myopathy should be kept in mind in case of sudden muscle pain and high CK levels during the treatment with daptomycin.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Daptomycin is a fermentation product produced by Streptomyces roseosporus, which can act on aerobic and anaerobic gram-pos- itive bacteria in its cyclic form.
📊
Temel Bulgular & Veri:Muscle pain, muscle weakness and increased creatine kinase (CK) levels (MM isoenzyme) are detected due to myopathy.
💡
Sonuç & Katkı:Myopathy should be kept in mind in case of sudden muscle pain and high CK levels during the treatment with daptomycin.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Daptomycin is a fermentation product produced by Streptomyces roseosporus, which can act on aerobic and anaerobic gram-pos- itive bacteria in its cyclic form. Daptomycin has activity against methicillin-resistant Staphylococcus aureus (MRSA), glycopeptide-in- termediate Staphylococcus aureus, coagulase-negative staphylococcus species, penicillin-resistant Streptococcus pneumoniae, enterococci, vancomycin-resistant bacteria such as Pediococcus, Leuconostoc and Lactobacillus, gram positive anaerobic bacteria including Clostridium difficile, Corynebacterium and Bacillus bacteria and peptostreptococci. The primary toxicity associated with daptomycin is myopathy, which is rare. Muscle pain, muscle weakness and increased creatine kinase (CK) levels (MM isoenzyme) are detected due to myopathy. Paresthesia and reversible paralysis can be observed infrequently. In this article, a case of daptomy- cin-associated creatine phosphokinase elevation is presented. Clinical signs and symptoms improved with normal CK levels after discontinuation of daptomycin. Myopathy should be kept in mind in case of sudden muscle pain and high CK levels during the treatment with daptomycin.

🔖

Bu Makaleye Atıf Yap

ÇAKAR, Z. Ş., KARAGÖZ, G., ALTUNAL, L. N., ÖZEL, A. S., ÖZTÜRK, S., ÇOMOĞLU, Ş., BEKTAŞOĞLU, M. F., DOĞAN, F., KADANALI, A. (2020). A Case of Increased Creatin Kinase Level Caused by Daptomycin. Haydarpaşa Numune Medical Journal, Cilt: 60 - Sayı: 4, 445–447. https://ajindex.com/articles/161611

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (9)

  1. Kosmidis C, Levine DP. Daptomycin: pharmacology and clini- cal use. Expert Opin Pharmacother 2010;11:615–25
  2. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treat- ment of Gram-positive bacterial infections. Clin Infect Dis 2004;38:864–70
  3. Finberg RW, Moellering RC, Tally FP, Craig WA, Pankey GA, Dellinger EP, et al. The importance of bactericidal drugs: future directions in infectious disease. Clin Infect Dis 2004;39:1314– 20
  4. Bozkurt GY, Kutlu H, Arslan A, Memikoğlu O. Yeni Bir Antibak- teriyel Ajan: Daptomisin. Ankara Üniversitesi Tıp Fakültesi Mecmuası 2010;63:085–8
  5. Ergüt Sezer B, Arman D. Deri ve Yumuşak Doku İnfeksiyon- larında Daptomisin Kullanımı. Yoğun Bakım Dergisi 2012;10:1–8
  6. Kömür S, Ulu A, Kurtaran B, İnal AS, Kuşçu F, Tekin D, Taşova Y. Sudden respiratory failure and eosinophilic pneumonia in patients treated with daptomycin: a report of five cases. Cukurova Med J 2016;41:396–99
  7. Sauermann R, Rothenburger M, Graninger W, Joukhadar C. Daptomycin: a review 4 years after first approval. Pharmacol- ogy 2008;81:79–91
  8. Özaras R, Tabak F. Daptomisin. Klimik Dergisi 2010;23:35–8
  9. Berg ML, Estes LL, Dierkhising RA, Curran B, Enzler MJ. Evalua- tion of impact of statin use on development of CPK elevation during daptomycin therapy. Ann Pharmacother 2014;48:320–7.